Police & Firemen s Retirement System of New Jersey Has $2.09 Million Stock Position in DaVita Inc. $DVA

Police & Firemen s Retirement System of New Jersey lessened its holdings in DaVita Inc. (NYSE:DVA) by 14.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,634 shares of the company’s stock after selling 2,429 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in DaVita were worth $2,085,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in shares of DaVita in the 1st quarter valued at approximately $364,000. LPL Financial LLC grew its holdings in DaVita by 36.2% during the first quarter. LPL Financial LLC now owns 18,689 shares of the company’s stock valued at $2,859,000 after purchasing an additional 4,968 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of DaVita by 31.9% in the first quarter. Victory Capital Management Inc. now owns 57,074 shares of the company’s stock valued at $8,731,000 after purchasing an additional 13,802 shares during the period. Caxton Associates LLP acquired a new stake in shares of DaVita in the first quarter worth $513,000. Finally, Sovran Advisors LLC bought a new stake in shares of DaVita during the 2nd quarter worth $472,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of research analyst reports. TD Cowen cut their target price on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research report on Monday, November 3rd. Barclays dropped their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th. Truist Financial set a $140.00 target price on DaVita in a research note on Tuesday, October 14th. Zacks Research downgraded DaVita from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 30th. Finally, Bank of America reduced their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, DaVita has a consensus rating of “Reduce” and a consensus price target of $148.00.

DaVita Stock Down 1.0%

Shares of DVA opened at $115.40 on Thursday. The stock’s 50-day moving average price is $126.60 and its 200 day moving average price is $134.86. DaVita Inc. has a 12-month low of $113.97 and a 12-month high of $179.60. The firm has a market capitalization of $8.15 billion, a price-to-earnings ratio of 11.88, a P/E/G ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a return on equity of 815.62% and a net margin of 5.80%.DaVita’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.